With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Biogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...

Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain ...

Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...

Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients ...

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness watchdog, NICE, said the drug isn't cost-effective.

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...

In the past couple of years, it received approvals for several other new drugs like Kisunla, Omvoh and Jaypirca and witnessed ...

LONDON — Britain's drug regulator approved the Alzheimer's drug Kisunla on Wednesday, but the government won't be paying for it after an independent watchdog agency said the treatment isn't ...

A modified dosing regimen with Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has shown a reduction in amyloid-related imaging abnormalities with oedema/effusion (ARIA-E). Lilly announced ...

UK Regulator Approves Second Alzheimer's Drug in Months but Government Won't Pay for It LONDON (AP) — Britain's drug regulator approved the Alzheimer's drug Kisunla on Wednesday, but the ...